Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis

British Journal of Pharmacology

Volumn 125, Issue 1, 1998, Pages 29-34

  Berry, C N ^a   Lunven, C ^a   Lechaire, I ^a   Girardot, C ^a   O'Connor, S E ^a  

^a SANOFI   (France)

Author keywords

Arterial thrombosis; Bleeding time; PAI 1 inhibition; Plasminogen activators; Rat venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; CHROMOGENIC SUBSTRATE; FIBRIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MA33H1; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; UNCLASSIFIED DRUG; VITRONECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; CAROTID ARTERY; CAVA VEIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK FACTOR; THROMBOGENESIS; THROMBOSIS; VEIN THROMBOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BLEEDING TIME; CROSS REACTIONS; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MALE; PIPECOLIC ACIDS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION INHIBITORS; RATS; THROMBOSIS; VENOUS THROMBOSIS;

EID: 0031708331     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702030     Document Type: Article

References (33)

1. ÅSTEDT, B., CASSLÉN, B., LECANDER, I., NILSSON, L. & NORGREN, L. (1993). Rebound increase of PAI-1 following local intraarterial rt-PA infusion, a possible cause of reocclusion. Blood Coagulation and Fibrinolysis, 4, 563-567.
2. AUDENAERT, A.-M., KNOCKAERT, I., COLLEN, D. & DECLERCK, P.J. (1994). Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive centre loop. J. Biol. Chem., 269, 19559-19564.
3. BARNES, C.S., FAINT, R.W., DWYER, M.C., CRITCHLEY, D.J.P., TEMPLETON, D., FOLKES, A.J., CHARLTON, P.A. & BEVAN, P. (1996). Effects of XR5118 on PAI-1 and tPA activity and arterial thrombus formation in the anaesthetised rat. Brit. J. Pharmacol., 118 (suppl.), 97P.
4. BERRY, C.N., GIRARD, D., LOCHOT, S. & LECOFFRE, C. (1994). Antithrombotic actions of argatroban in rat models of venous 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. Br. J. Pharmacol., 113, 1209-1214.
5. BIEMOND, B.J., LEVI, M., CORONEL, R., JANSE, M.J., TEN CATE, A.W. & PANNEKOEK, H. (1995). Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen-activator inhibitor type 1-neutralizing antibody. Circulation, 91, 1175-1181.
6. CHARLTON, P.A., FAINT, R.W., BENT, F., BRYANS, J., CHICARELLI-ROBINSON, I., MACKIE, I., MACHIN, S. & BEVAN, P. (1996). Evaluation of a low molecular modulator of human plasminogen activator inhibitor-1 activity. Thromb. Haemostas., 75, 808-815.
7. DAWSON, S. & HENNEY, A. (1992). The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis. 95, 115-117.
8. DAWSON, S.J., WIMAN, B., HAMSTEN, A., GREEN, F., HUMPHRIES, S. & HENNEY, A.M. (1993). The two allele sequences of a common polymorphism in the promoter of the plasminogen-activator inhibitor-1 (PAI-1) gene respond differently to interleukin 1 in HepG2 cells. J. Biol. Chem., 268, 10739-10745.
9. DEBROCK, S. & DECLERCK, P.J. (1997). Neutralization of plasminogen activator inhihitor-1 inhibitory properties: identification of two different mechanisms. Biochim. Biophys. Acta., 1337, 257-266.
10. DEBROCK, S. & DECLERCK, P.J. (1998). Identification of a functional epitope in plasminogen activator inhihitor-1, not localised in the reactive centre loop. Thromb. Haemostas., 79, 597-601.
11. DECLERCK, P.J., DE MOL, M., VAUGHAN, D.E. & COLLEN D. (1992). Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a non-inhibitory substrate for tissue-type plasminogen activator. J. Biol. Chem., 267, 11693-11696.
12. ERICKSON, L.A., FICI, G.J., LUND, J.E., BOYLE, T.P., POLITES, H.G. & MAROTTI, K.R. (1990). Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor 1 gene. Nature, 346, 74-76.
13. ERIKSSON, B.I., ERIKSSON, E., GYZANDER, E., TEGER-NILSSON, A.-C. & RISBERG, B. (1989). Thrombosis after hip replacement relationship to the fibrinolytic system. Acta Orthop. Scand., 60, 159-163.
14. ERIKSSON, P., KALLIN, B., VANT'HOOFT, F.M., BAVENHOLM, P. & HAMSTEN, A. (1995). Allelic specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc. Natl. Acad. Sci., 92, 1851-1855.
15. FREUND, M., CAZENAVE, J.-P., COURTNEY, M., DEGRYSE, E., ROITSCH, C., BERNAT, A., DELEBASSEE, D., DEFREYN, G. & MAFFRAND, J.-P. (1990). Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats. Thromb. Haemostas., 63, 187-192.
16. FREIDERICH, P.W., LEVI, M., BIEMOND, B.J. CHARLTON, P., TEMPLETON, D., VAN ZONNEVELD, A.J., BEVAN P.J., PANNKOEK, H. & TEN CATE J.W. (1997). Novel low-molecular weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation. 96, 916-921.
17. HANTGEN, R.R. (1994). PAI-1 released from cultured human endothelial cells delays fibrinolysis and is incorporated into the developing fibrin clot. Fibrinolysis, 8, 104-112.
18. HOYLAERTS, M., LIJNEN, H. R. & COLLEN, D. (1981). Studies on the mechanism of the antifibrinolytic actions of tranexamic acid. Biochem. Biophys. Acta., 673, 75-85.
19. KEIJER, J., LINDERS, M., VAN ZONNENFELD, A.J., EHRLICH, H.J., DE BOER, J.P. & PANNEKOEK H. (1991). The interaction of plasminogen activator inhibitor-1 (PAI-1) with plasminogen activators (t-PA, u-PA) and fibrin: localization of interaction sites and physiological relevance. Blood, 78, 401-409.
20. KRUITHOF, E.K.O., TRAN-THANG, C., RANSIJN, A. & BACHMANN, F. (1984). Demonstration of a fast acting inhibitor of plasminogen activators in human plasma. Blood, 64, 907-913.
21. LEVI, M., BIEMOND, B.J., VAN ZONNEVELD, A.J., TEN CATE, A.W. & PANNEKOEK, H. (1992). Inhibition of plasminogen activator inhibitor-1 results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation, 85, 305-312.
22. MANSFIELD, M.W., STICKLAND, M.H. & GRANT P.J. (1995). Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb. Haemostas., 74, 1032-1034.
23. MOTTONEN, J., STRAND, A., SYMERSKY, J., SWEET, R.M., DANLEY, D.E., GEOHEGAN, K.F., GERARD, R.D. & GOLDSMITH, F.J. (1992). Structural basis of latency of plasminogen activator inhibitor-1. Nature, 355, 270-273.
24. MUNCH, M., HEEGAARD, C.W. & ANDREASEN, P.A. (1993). Interconversions between active, inert and substrate forms of denatured refolded type-1 plasminogen activator inhibitor. Biochim. Biophys. Acta., 1202, 29-37.
25. OSSEI-GERNING, N., MANSFIELD, M.W., STICKLAND, M.H., WILSON, I.J. & GRANT, P.J. (1997). Plasminogen activator inhibitor-1 promoter 4G 5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterised by coronary angiography. Arterioscler. Thromb. Vasc. Biol., 17, 33-37.
26. RAPOLD, H.J., GRIMAUDO, V., DECLERK, P.J., KRUITHOF, E.K.O. & BACHMANN, F. (1991). Plasma levels of plasminogen activator inhibitor type 1, β-thromboglobulin and fibrinopeptide A before during, and after treatment of acute myocardial infarction with Alteplase. Blood, 78, 1490-1495.
27. REILLY, C.F., FUJITA, T., MAYER, E.J. & SIEGFRIED, M.A. (1991). Both circulating and clot-bound plasminogen activator inhibitor 1 inhibit endogenous fibrinolysis in the rat. Arterioscler. Thrombos., 11, 1276-1286.
28. TALBOT, M.D., AMBLER, J.A., BUTLER, K.D., LEES, C.M., MITCHELL, K.A., PETERS, R.F., TWEED, M.F. & WALLIS, R.B. (1991). The effects of recombinant desulphatohirudin on arterial thrombosis in rats. Haemostasis, 21 (suppl. 1), 73-79.
29. URANO, T., STRANDBERG, L., JOHANSSON, L.B. & NY, T. (1992). A substrate-like form of plasminogen activator inhibitor-1. Conversions between different forms by sodium dodecyl sulphate. Eur. J. Biochem., 209, 985-992.
30. ab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis. Thromb. Haemostas., 77, 965-969.
31. VAN MEIJER, M., KLEIN GEBBINK, R., PREISSNER, K. & PANNEKOEK, H. (1994). Determination of the vitronectin binding site on plasminogen activator inhibitor type 1 (PAI-1). FEBS Lett., 352, 342-346.
32. VAUGHAN, D.E., DECLERCK, P.J., VAN HOUTTE, E., DE MOL, M. & COLLEN, D. (1992). Reactivated recombinant plasminogen activator inhibitor (rPAI-1) effectively prevents thrombolysis in vivo. Thromb. Haemostas., 68, 60-63.
33. WIECZORIC, I., LUDLAM, C.A. & FOX, K. (1994). Tissue type plasminogen activator and plasminogen activator inhibitor activities as predictors of adverse events in unstable angina. Am. J. Cardiol., 74, 424-429.